Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|CEP-11981||ESK981|CEP11981|CEP 11981||CEP-11981 is a multikinase inhibitor that targets Tie2, Vegfr1-3, and Fgfr1, which may inhibit tumor angiogenesis and lead to tumor inhibition (PMID: 23621441, PMID: 25152243).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||Advanced Solid Tumor||not applicable||CEP-11981||Phase I||Actionable||In a Phase I trial, CEP-11981 demonstrated safety and preliminary efficacy, resulted in stable disease in 51% (19/37) of patients with advanced solid tumors (PMID: 25152243).||25152243|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT03456804||Phase II||CEP-11981||ESK981 in Treating Patients With Metastatic Castrate-Resistant Prostate Cancer||Active, not recruiting||USA||0|
|NCT03562507||Phase II||CEP-11981 CEP-11981 + Nivolumab||Phase 2 Multi-center Trial of ESK981 in Combination With Nivolumab in Patients With Metastatic Renal Cell Carcinoma||Recruiting||USA||0|